Structural GenomiX Acquires Troxatyl® from Shire
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 51 (Table of Contents)
Published: 4 Sep-2004
DOI: 10.3833/pdr.v2004.i51.778 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Structural GenomiX entered into license agreement with Shire BioChem to acquire worldwide rights for anticancer drug, Troxatyl® (troxocitabine) for treating acute myeloid leukemia and solid tumors...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS